{"denoms":[{"counts":[{"groupId":"BG000","value":"59"}],"units":"Participants"}],"groups":[{"description":"This was a follow-up safety study where study treatment was not administered. Patients came from BGG492 studies where patients were previously exposed to \\> 28 days of BGG492 50 mg, 100 mg or 150 mg given orally three times a day","id":"BG000","title":"BGG492"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.58","value":"43.2"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"31"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"28"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Gender","unitOfMeasure":"Participants"}],"populationDescription":"Includes all patients who signed the informed consent form for the study."}